New blood test aims to catch lung cancer early in underserved groups

NCT ID NCT06716580

Recruiting now Diagnosis Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study is testing a new blood test that looks for pieces of tumor DNA (EGFR mutations) to screen for lung cancer in healthy people aged 50-80 who are of East Asian, Southeast Asian, or Hispanic/Latinx background and do not currently smoke. The goal is to find lung cancer early in those who cannot get regular CT scans. The test is not yet proven, and positive results will be double-checked with standard methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood test (ctDNA assay)
What this could lead to: If successful, this blood test could provide a simple, accessible way to catch EGFR-positive lung cancer early in high-risk groups who are not eligible for standard screening.
What could go wrong: This is an early-stage screening study, not a treatment trial. The test may produce false positives or negatives, and it only detects certain EGFR mutations, missing other lung cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR GENE MUTATION LUNG CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute South Shore
NOT_YET_RECRUITING

South Weymouth, Massachusetts, 02190, United States
Dana-Farber Cancer Institute at Steward St. Elizabeth's
NOT_YET_RECRUITING

Brighton, Massachusetts, 02135, United States
Dana-Farber Cancer Instiute Merrimack Valley
NOT_YET_RECRUITING

Methuen, Massachusetts, 01844, United States
Massachusetts General Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.